Symposium: The Value of Real World Evidence in Psychedelic Research

Value of the Information & Strength of the Argument

The value of the information is high, as it addresses a critical gap in psychedelic research methodology. The speakers provide concrete examples of RWE applications, such as the medical cannabis registry T21 and the Australian and Canadian access programs, demonstrating the practical utility of these approaches. The argumentation is solid, systematically presenting the limitations of RCTs and the potential of RWE, while acknowledging the challenges such as data quality. The speakers avoid overstating their case, emphasizing that RWE is complementary, not a replacement, for RCTs. The inclusion of diverse perspectives (pharmacology, epidemiology, clinical practice) strengthens the overall argument.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is generally high, with speakers referencing specific studies and registries, though not always with formal citations. The quality of sources is good, as the speakers are leading experts in the field. The title accurately reflects the content, which is focused on the value of real-world evidence. The session is well-structured, with clear transitions between speakers. No comments were provided, so no analysis of public feedback is included.

The title accurately reflects the content, which focuses on the value of real-world evidence in psychedelic research.

8/10

The symposium features recognized experts in psychedelic research (Drs. Schlag, Erritzoe, and Nutt) who present a balanced view on the limitations of RCTs and the potential of real-world evidence. The content is well-structured, references ongoing studies and registries, and acknowledges limitations. However, it is primarily an expert opinion session rather than a systematic review, and some claims lack specific citations.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction by Dr. Anne Katrin Schlag, setting the stage for the symposium.
• 05:00Discussion of limitations of RCTs in psychedelic research, including blinding and expectancy effects.
• 10:00Examples of real-world evidence approaches, including registries and naturalistic studies.
• 15:00Dr. Michael Linski discusses the broader context of drug licensing and the potential of big data.
• 20:00Dr. David Erritzoe presents citizen science initiatives and self-blinding studies.
• 25:00Panel discussion and Q&A session with the audience.

• Drug Science — Mentioned as the organization hosting the symposium and conducting research on medical cannabis and psychedelics.
• T21 Medical Cannabis Registry — Referenced as an example of a real-world evidence registry for medical cannabis.
• Compass Pathways — Mentioned in the context of large-scale psilocybin trials.

• Real-world evidence in psychedelic research — A recent article discussing the use of RWE in psychedelic research, supporting the symposium's arguments.

• RCTs as Gold Standard — Some researchers argue that RCTs remain the gold standard and that RWE may introduce bias, a perspective not fully addressed in the symposium.